DHX32

Across TCGA pan-cancer cohorts, DHX32 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DHX32 data layer compared with 17 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in acute myeloid leukemia (LAML), where higher DHX32 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DHX32 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LAML, LUAD, and PRAD are the cancer types where DHX32 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LAML	DFS	Median	All	0.140	0.582	.020	12	view →
LUAD	OS	Median	All	0.368	0.686	.019	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	All	0.961	0.652	.036	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DHX32–LAML (DFS)

Open the LAML breakdown →